Join our daily newsletter At The Bell to receive exclusive market insights
Recce Pharmaceutical Ltd (ASS:RCE) has reached a milestone in its Phase II clinical trial to test the efficacy of its RECCE 327 topical gel for treatment of Acute Bacterial Skin and Skin Structure Infections (or ABSSSI) – with 20 of 30 total patients being dosed.
Data taken from the trial indicates the gel – also known as R327G – has yielded a strong effective response from participants, all of whom have reported positive outcomes after treatment, including total cure or notable improvement.
At the same time, no Serious Adverse Events (SAEs) have been reported for the gel.
Chief Medical Advisor Dr Alan W Dunton said all indicators boded well from the trial, and underpinned Recce’s success with development and assessment of R327G.
“These interim results reflect a remarkable advancement in our journey to address critical unmet medical needs in anti-infective therapies,” he said.
“The robust response we are seeing with R327G is encouraging, especially as we near completion of the Phase II trial.
“Achieving a response of complete cure or notable improvement in all patients treated so far highlights the potential impact of R327G in treating complex bacterial infections, including diabetic foot infections.”
Recce shares moved up on the news, and at 12:51 AEDT, they were trading at 45 cents – a rise of 1.12% since the market opened.
Join the discussion: See what HotCopper users are saying about Recce and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
